Jacqueline C. Barrientos, MD, MS

Mount Sinai Comprehensive Cancer Center

Poster(s):

• 1409 - Factors influencing physician’s choice of fixed-duration ibrutinib+venetoclax or continuous ibrutinib monotherapy in the treatment of patients with previously untreated CLL: physician questionnaire results from the prospective phase 2 TAILOR study

• 1411 - Outcomes, inequities, and access to front-line preferred therapies for chronic lymphocytic leukemia in the United States: a real-world evidence study